Democritus University of Thrace (DUTH)
Πολυπαραγοντική μελέτη ασθενών με νεφρική οστεοδυστροφία που βρίσκονται στο 3ο και 4ο στάδιο χρόνιας νεφρικής ανεπάρκειας
Abstract
dc:descriptionChronic kidney disease (CKD) is increasingly recognized as a global public health problem. Risk factors for CKD occurrence, its pathophysiology, as well as the clinical picture with multi systemic involvement, make CKD a syndrome that affects a large number of patients with pre-existing comorbidity (arterial hypertension, diabetes mellitus-DM, coronary heart disease) and also an entity that has an important and independent role in the morbidity and mortality of patients, especially through the wide range of cardiovascular disease (CVD), which is the leading cause of death in these patients. During the last decade, 2 important biomarkers, Fibroblast Growth Factor 23 (FGF-23) and α-Klotho protein have gained the attention of the nephrology community, because of their contribution in CKD onset and progression.The present thesis studied 128 patients with CKD, mainly from the 3rd and 4th stage, and less from the other 3 stages, not in renal replacement therapy (RRT). The distribution of patients per CKD stage was as follows: 1st and 5th stage 6 patients, 2nd stage 18 patients, 3rd stage 66 patients, and 4th stage 32 patients. All of them underwent extensive clinical and laboratory testing during the first visit, followed by a follow-up study with recording parameters related to the level of renal function. A large number of variables related to demographic and somatometric characteristics, comorbidity factors, blood pressure values, renal function levels, routine laboratory tests and those related to mineral and bone metabolism disorders (CKD-MBD) were determined and recorded in all patients, as well as the plasma levels of the carboxyl terminal FGF-23 (c-termFGF-23) and the soluble form of α-Klotho protein (sKlotho). In addition, all patients underwent glomerular filtration rate (GFR) measurement by exogenous intravenous administration of a radiolabeled tracer, as well as imaging-radiological examination for the presence of vascular calcifications in the abdominal aorta. During the follow-up study (median value 36, range 2-60 months), 40 patients out of a total of 128 (31.2%) either initiated RRT or died (31 and 9 respectively). The primary endpoint of the study or event was a composite of initiation of RRT or death, whichever came first, that was recorded for all patients at the end of their follow-up. All deaths were due to cardiovascular causes. From all the results that emerged from the study, the most important points will be mentioned, from the univariate and multivariate correlation of the variables with each other.During the statistical analysis of the data, the 128 patients who participated in the study “were categorized” by 3 different ways. According to the classical staging of KDOQI 2002, they were classified into 5 CKD stages, according to the interaction of 3 variables, measured GFR (mGFR), serum phosphorus (P) and plasma sKlotho, they were divided into 3 groups called regression groups A, B and C and finally according to the combinations of lower and higher value, compared to the median one of c-termFGF-23 and sKlotho plasma levels, they were divided into 4 groups G1, G2, G3 and G4. Many variables differed significantly between the above 3 different patient classifications, including c-termFGF-23 and sKlotho. It should be noted that the 2 biomarkers also differed significantly between the group of patients and that of healthy individuals, who were considered as a control group. Furthermore, there was a significant difference in their plasma levels that increased for c-termFGF-23 and decreased for sKlotho, as the CKD progressed, from stage 3 and thereafter.From the division of patients into 3 regression groups A, B and C, based on mGFR and P serum levels, an interesting interaction was seen between mGFR, P and sKlotho. The 3 regression groups showed a significant correlation with the 5 CKD stages, with group A corresponding almost exclusively to the 1st and 2nd CKD stage, while groups B and C included the other 3 stages, with the frequency of group B to decrease and of group C to increase gradually from the 3rd to the 5th CKD stage. Both c-termFGF-23 and sKlotho differed significantly among the 3 groups, with the difference of the latter being much more clear. The above correlations and interactions could potentially be translated as a “tight” collaboration of α-Klotho protein and P during CKD progression, depending on the levels of renal function, expressed by mGFR. Also, it is worthy to note that the transition from regression group A to groups B and C was based only on mGFR levels (with a cut-off value of 60.85 ml/min/1.73m2), while the transition from group B to C was further based on P serum levels (with a cut-off value of 3.7 mg/dl). The interaction of α-Klotho with P in CKD is a well-established knowledge and may be indicative of the need for early intervention in the regulation of P serum levels, even when they are within normal limits.The presence of vascular calcifications (VC) in the abdominal aortic wall, as these were assessed by the Aortic Abdominal Calcification (AAC) score, was positively correlated with many variables, such as cardiovascular risk factors (old age, presence of DM, history of CVD, increased waist-to-hip ratio) or others related to impaired renal function and CKD-MBD. There was a significant difference of AAC score value in relation to plasma levels of c-termFGF-23, with higher values of the former being associated with higher values of the latter, while something similar was not observed for sKlotho plasma levels. However, the multivariate analysis showed that AAC score was independently associated, among other variables, with sKlotho and not with c-termFGF-23.The relationship of c-termFGF-23 and sKlotho with CKD progression was evident, since the variable called final GFR (fGFR) recorded at the end of the follow-up for all patients, showed a negative correlation with the first and a positive one with the second biomarker. At the same time, when patients were divided into 2 groups, depending on c-termFGF-23 and sKlotho plasma levels, lower and higher than their median value (218.8 RU/ml and 479.8 pg/ml respectively), a significant difference in their survival, according to the presence of event, was shown between the 2 groups. Thus, patients with lower than median c-termFGF-23 values or higher than median sKlotho values had longer event-free survival, compared with the opposite condition. A similar difference was observed between the 3 regression groups A, B and C, with the transition from group A to group C being associated with a worsening of survival.Apart from the relationship of patients' survival with each biomarker separately, the corresponding relationship of their combination, as couples based on their lower and higher value compared to the median one, was much more interesting. Thus, as already mentioned, 4 groups G1, G2, G3 and G4 were formed, each of them containing a couple. These couples were G1: low c-termFGF-23/high sKlotho, G2: low c-termFGF-23/low sKlotho, G3: high c-termFGF-23/high sKlotho and G4: high c-termFGF-23/low sKlotho. The statistical analysis in various ways showed that the best survival, according to the presence of event, appeared in the G1 group, the worst in the G4 group, while in the other 2 groups, G2 and G3, the survival was comparable in a non adjusted and adjusted model. In other words, the combination of low FGF-23 and high α-Klotho is a favorable condition for a better outcome of patients with CKD, while the opposite combination is associated with clearly worse results. When examining the relationship between the decrease in GFR over time in the 4 groups, it appeared that although the GFR decreased significantly in all groups, there was no correspondingly significant difference in the slope of the GFR fall between the groups. In other words, the value of GFR decreased over time in all 4 groups, but this occurred regardless of the combination of low/high values of c-termFGF-23 and sKlotho. The above observation turned to be significant, especially regarding to the G4 group, when the statistical model was adjusted for potential confounders.Finally, the relationship of the 4 groups with the presence of VC also showed that the combination of low c-termFGF-23 with low sKlotho was probably more "dangerous" for the appearance of VC, compared to the combination of high c-termFGF-23 with high sKlotho. This observation could perhaps indicate the significant contribution of α-Klotho to the vascular calcification process, which may surpass that of FGF-23. Besides, the relationship of α-Klotho with CVD and especially VC, has also been a wide field of research, with most studies converging that the lack of this protein, which characterizes CKD, has adverse effects on the vasculature of these patients.In conclusion, the present thesis recorded and studied a large number of parameters-variables related to CKD-MBD and CVD, focusing on the newer biomarkers FGF-23 and α-Klotho protein. The combination of FGF-23 and α-Klotho levels in patients with CKD stage 1-5, not in RRT, was found to be independently associated with progression to end-stage CKD and RRT initiation , as well as with cardiovascular mortality. Also, the levels of mGFR, serum P and plasma sKlotho, acting synergistically, may also have a prognostic role in the clinical outcome of patients, possibly enabling a type of “classification” of patients, which is highly relevant to classic staging of CKD. The identification of the 2 biomarkers together and not just each one separately, may offer additional prognostic possibilities, with the potential goal of modifying FGF-23 and α-Klotho levels close to the “unknown normal” limits, thus improving the clinical outcome of this high risk, especially for CVD, group of patients.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Manou, Eleni
- Μάνου, Ελένη
Subjects
dc:subject × 14- Χρόνια νεφρική νόσος
- Διαταραχές των οστών και των μετάλλων στη χρόνια νεφρική νόσο
- Αυξητικός παράγοντας των ινοβλαστών 23
- Πρωτεΐνη α-Κλωθώ
- Chronic kidney disease
- Mineral and bone disorders in chronic kidney disease
- Fibroblast growth factor 23
- α-Klotho protein
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Νεφρολογία
- Clinical Medicine
- Medical and Health Sciences
- Nephrology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49973